Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
ES2B-C001
/
ExpreS2ion
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
ES2B-C001
/
ExpreS2ion
Enrollment open:
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2 Expressing Metastatic Breast Cancer.
(clinicaltrials.gov) - Jan 9, 2025
P1
, N=27, Recruiting,
Sponsor: ExpreS2ion Biotechnologies
Not yet recruiting --> Recruiting
|
|||||||||
ES2B-C001
/
ExpreS2ion
New P1 trial:
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2 Expressing Metastatic Breast Cancer.
(clinicaltrials.gov) - Dec 26, 2024
P1
, N=27, Not yet recruiting,
Sponsor: ExpreS2ion Biotechnologies
||||||||||
ES2B-C001
/
ExpreS2ion
Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis
(Section 24; Poster Board #7) - Mar 14, 2023 - Abstract #AACR2023AACR_2594;
Antibodies inhibited the 3D growth of human HER-2+++ and HER-2++ breast cancer cells, of trastuzumab resistant cells and of gastric carcinoma cells. Vaccination increased interferon-gamma secreting cells in the spleen, as evaluated by ELISPot (21
|
|||||||||
ES2B-C001
/
ExpreS2ion
,
Herceptin
(trastuzumab) /
Roche
Journal:
Prevention and Therapy of Metastatic HER-2 Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine.
(Pubmed Central) - Oct 29, 2022
ES2B-C001 is a promising candidate vaccine for the therapy of tumors expressing HER-2. Preclinical results warrant further development towards human clinical studies.
||||
||||||
ES2B-C001
/
ExpreS2ion
Clinical:
ExpreS2ion provides an update on its novel breast cancer vaccine candidate ES2B-C001 https://t.co/YrwCDIo5bs
(Twitter) - Feb 8, 2022